01927nas a2200265 4500000000100000008004100001260001600042653001900058653001500077653001400092653003800106653001100144653001200155653000900167653001900176100001200195700001200207700001000219245006600229856006400295300001100359490000600370520127100376022001401647 2010 d c2010 Jun 3010aAutoantibodies10aBiomarkers10aCeramides10aEnzyme-Linked Immunosorbent Assay10aHumans10aleprosy10aMale10aNervous System1 aSingh K1 aSingh B1 aRay P00aAnti-ceramide antibodies in leprosy: marker for nerve damage? uhttp://www.jidc.org/index.php/journal/article/view/20601789 a378-810 v43 a
BACKGROUND: Leprosy is a chronic infectious disease primarily affecting the peripheral nervous system and skin. Multibacillary leprosy is associated with nerve damage which could contribute to myelin alteration. As ceramide is a constituent of myelin sheath, the present study aimed to compare anti-ceramide antibody titre in paucibacillary and multibacillary leprosy patients with controls.
METHODOLOGY: Serum levels of anti-ceramide antibody were measured using enzyme-linked immunosorbent assays (ELISA) in 50 leprosy patients (25 paucibacillary and 25 multibacillary) and 25 healthy controls. Results were reported in OD units as mean +/- SD and analyzed by Chi square test (significance at p < 0.05).
RESULTS: Patients suffering from multibacillary leprosy had significantly higher anti-ceramide antibody serum levels compared to paucibacillary leprosy patients and healthy controls (p < 0.005).
CONCLUSIONS: Since nerve damage is the most debilitating effect of leprosy, the search for a serum marker for assessing nerve damage is required in countries where leprosy is still widespread. In multibacillary leprosy patients, the role of anti-ceramide antibody as a marker for nerve damage should be explored.
a1972-2680